Announcements Trials
Browse Landscape

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sleep Apnea, Obstructive 1Skin Diseases 1Polycythemia Vera 1Neoplasms by Site 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1Breast Diseases 1Brain Neoplasms 1Body Weight Changes 1Anorexia 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of the Prostate 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 4Pemetrexed 3pembrolizumab 2patritumab 2osimertinib 2Sunitinib 2Standard of Care 2Paclitaxel 2Irinotecan 2Cisplatin 2Ascorbic Acid 2valrubicin 1pralsetinib 1palbociclib 1napabucasin 1linifanib 1genexol-PM 1dostarlimab 1alectinib 1Watchful Waiting 1Sorafenib 1Ramucirumab 1Patient Reported Outcome Measures 1Mitomycin 1KRN-330 1Interleukin-2 1Indocyanine Green 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Site × Watchful Waiting × Clear all
NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡